# Genentech, Inc.: Phase 1 study in Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma (388 participants)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Genentech, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma |
| NCT ID | NCT07859085 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Colorectal Neoplasms; Pancreatic Ductal Adenocarcinoma |
| Intervention types | drug, biological |
| Target enrollment | 388 |
| Posted | 2026-10-05 |
| Planned start | 2026-10-31 |
| Event | Newly registered study |
| Event date | 2026-10-05 |

## Why this score
- Industry sponsor (buys outsourced services).
- 388 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07859085). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.